Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
Hereditary pulmonary alveolar proteinosis (hPAP) is an autosomal recessive disorder of surfactant clearance caused by dysfunction of the GM-CSF receptor α chain (CSF2RA), leading to hereditary pulmonary alveolar proteinosis. To date, three unrelated early-onset hPAP patients have been reported with biallelic CSF2RA lesions: a 3-year-old girl with homozygous CSF2RA deletion unmasked by a complex X chromosome rearrangement (PMID:23918747), a 3-year-old patient and her homozygous but asymptomatic sister (PMID:23206404), and a 4-year-old girl from a consanguineous family carrying homozygous CSF2RA deficiency (PMID:39621143). One additional affected sibling segregated the identical homozygous deletion, confirming autosomal recessive transmission (PMID:23206404). In all cases, surfactant accumulated in the alveoli, manifesting with respiratory failure and short stature due to concomitant SHOX deletion in the first report (PMID:23918747). Functional assays revealed impaired GM-CSF signalling in alveolar macrophages, and hematopoietic stem cell transplantation successfully restored surfactant clearance in the severe case (PMID:39621143). No studies have disputed the CSF2RA–hPAP association. Overall, the limited number of probands with consistent genetic and functional data supports a Limited clinical validity classification. Key Take-home: Biallelic CSF2RA loss confirms recessive hPAP, informing diagnostic testing and curative HSCT strategies.
Gene–Disease AssociationLimited3 probands with biallelic CSF2RA lesions and consistent functional rescue by HSCT Genetic EvidenceLimited3 probands and one segregating sibling with homozygous CSF2RA variants Functional EvidenceModerateIn vitro GM-CSF signalling impairment and rescue by HSCT demonstrating mechanism of disease |